Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Data spans seven presentations across both solid tumors and hematologic malignancies, providing…
Anaveon Announces Presentation of Positive ANV600 Clinical Data at ASCO 2026 and Actively Seeks Partners for its Legacy Oncology Portfolio
BASEL, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage preclinical…
Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia,…
BostonGene Receives Frost & Sullivan’s 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions,reducing risk and accelerating patient…
Laigo Bio completes final close of oversubscribed seed financing of 17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m…
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio
Acquisition positions Servier as a leader in pediatric low-grade glioma and expands…
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing
Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”),…
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
February 24, 2026 16:30 ET | Source: Cardiff Oncology, Inc. Reported positive…
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
February 12, 2026 21:18 ET | Source: Coherus Oncology, Inc. REDWOOD CITY,…
